drugset
Drugs / IDE892
last change Mar 2026 re-read 2 minutes ago

IDE892

targets PRMT5 via inhibition

Developed for
biliary tract cancer · esophageal adenocarcinoma · esophageal squamous cell carcinoma · gastric adenocarcinoma · gastroesophageal cancer · lung adenocarcinoma · malignant pancreatic neoplasm · peritoneal mesothelioma
+3 more · pleural mesothelioma · urinary bladder cancer · urothelial carcinoma
Investigated by
IDEAYA Biosciences

Trials 1 · a red edge is where a trial was stopped

today NCT07277413 · Ph 1
20272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07277413 Mar 2026 → Apr 2028 expected biliary tract cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastric adenocarcinoma +7 IDEAYA Biosciences Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as IDE892 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07277413 ↗
Action Inhibit “IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5)” NCT07277413 ↗
Target PRMT5 “IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5)” NCT07277413 ↗